Werth VP, Hejazi E, Pena SM, et al. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis. ACR 2017, abstract 7L.
Auto-immuunziekten verhogen risico op hartfalen
jan 2026 | Arthritis psoriatica, Hartfalen, RA, Sclerodermie, SLE